Cooley’s 2022 Life Sciences M&A Year in Review
Cooley M&A
JANUARY 25, 2023
Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company. The need for big pharma to fill looming revenue gaps as medicines lose marketing exclusivity is balanced against increasing caution in boardrooms about making large, risky bets.
Let's personalize your content